Genetically engineered cell membrane-coated nanoparticles for targeted delivery of dexamethasone to inflamed lungs

Summary

This preclinical study asks whether a cell-membrane coating can be genetically programmed to recognize a common feature of inflamed vasculature and thereby concentrate an anti-inflammatory drug in diseased lungs. Inflamed endothelial cells frequently increase expression of vascular cell adhesion molecule-1. The researchers engineered source cells to constitutively display very late antigen-4, a natural VCAM-1 binding partner, then wrapped their plasma membranes around polymeric nanoparticle cores. In vitro, these coated particles showed stronger affinity for cells overexpressing VCAM-1, confirming that the engineered membrane transferred the intended targeting interaction. Loading dexamethasone into the cores subsequently improved delivery to inflamed lung tissue and produced significant therapeutic activity in vivo. The main finding is that a natural receptor–ligand pair can be installed on a biomimetic carrier through source-cell engineering, adding a defined targeting function while retaining the advantages of membrane camouflage. This is significant as a modular route to direct drugs toward inflammatory lesions characterized by VCAM-1, rather than relying only on passive accumulation. The abstract supports proof of concept in lung inflammation but does not specify comparative exposure, disease model, durability, or safety of constitutive VLA-4 display.